(SeaPRwire) –
By: Oliver Hawthorne
Linkage Global’s recent coma research award masks a critical industry tension. Wellness tech firms increasingly lean on preliminary, unvalidated data to court investors and consumers. This case exposes the gap between celebrating exploratory research and the rigorous work needed to turn it into safe, effective solutions. Many in the field worry this trend could erode trust in non-pharmacological approaches long-term.
On August 25, 2026, Linkage Global Inc. (NASDAQ: UZX) announced Professor Zeng Yan, chief scientist at its intellectual property partner ClickClack, won the “Clinical Contribution Award for Deep Coma Awakening.” The award came from the Guangdong Second Hospital of Traditional Chinese Medicine’s Coma Arousal and Rehabilitation Center. It recognized a two-year observational study of 407 deep coma patients. Zeng, developer of the “Micro-brain” sonic healing system, led the study combining micro-brain sound wave music with traditional acupuncture. The study was uncontrolled and single-center, with no control group or randomization. As of December 2025, 32 patients (7.86%) had awakened during observation. Another 252 (61.9%) saw a 9-point or higher increase on the Glasgow Coma Scale. But the release warns these outcomes can’t be attributed to the protocol. They might reflect spontaneous recovery or concurrent care. The data hasn’t been peer-reviewed, and no regulatory authority has approved the protocol or any related product. Linkage and the hospital are now launching a second-stage study into non-pharmacological approaches for cognitive impairment and sleep disorders. This research is investigational, not conducted under an FDA or comparable authority’s investigational application. The “Phase II” label refers only to the parties’ internal research sequence, not a regulated trial phase.
Linkage, founded in March 2022 and headquartered in Tokyo, builds AI-enabled wellness products via its proprietary Human Resonance OS. The system integrates neural acoustic algorithms, original wellness audio copyrights, and smart wearables for B2B and B2C markets. Its current portfolio centers on four lifestyle scenarios: carrying, sleeping, staying, traveling. Chairman Zhihua Wu says the company will use the new study’s data to inform its product architecture. It aims to pursue broader non-pharmacological wellness applications and eventually compete in the mood-regulating equipment market for clinical and consumer use. But this path is riddled with uncertainties. The company can’t guarantee the second-stage research will be completed, produce favorable results, or lead to commercially viable products. Without rigorous, peer-reviewed data or regulatory approval, Linkage risks overpromising to investors and consumers. Consumers may mistakenly view its wellness products as medical devices, leading to disappointment if they don’t deliver clinical outcomes. Investors face the risk that the research won’t translate into revenue growth. The only viable end-game here is for Linkage to prioritize rigorous clinical validation over marketing hype. Without that, it will struggle to establish credibility in both the consumer wellness and clinical tech spaces.
Author bio: Oliver Hawthorne, principal correspondent at TechGlobal Review, covers AI wellness and medical tech innovation across Asia and North America.